{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:46:31Z","timestamp":1793213191736,"version":"4.5.0"},"reference-count":279,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0529400"],"award-info":[{"award-number":["2024ZD0529400"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573732"],"award-info":[{"award-number":["82573732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Natural Science Foundation of China Major Joint Project on Key Scientific Issues of Lung Cancer","award":["82241235"],"award-info":[{"award-number":["82241235"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National High-Level Talents Special Support Program","award":["KA0120231004"],"award-info":[{"award-number":["KA0120231004"]}]},{"name":"Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors targeting the PD-1\/PD-L1 and CTLA-4 axes have fundamentally transformed its treatment landscape. This narrative review traces the evolution of NSCLC immunotherapy, from advanced-stage monotherapy and chemoimmunotherapy to its critical expansion into early-stage disease, highlighting the paradigm shift brought by neoadjuvant, adjuvant, and perioperative strategies. We examine essential clinical challenges, including optimal treatment duration, management of brain metastases, immune-related adverse events, and mechanisms of primary and acquired resistance, with a focus on genomic alterations like\n                    <jats:italic>KRAS<\/jats:italic>\n                    co-mutations with\n                    <jats:italic>STK11<\/jats:italic>\n                    and\n                    <jats:italic>KEAP1<\/jats:italic>\n                    . Furthermore, we critically evaluate the evolving biomarker landscape, moving beyond PD-L1 to encompass circulating tumour DNA, microbiome composition, and multiparametric approaches like T-cell receptor clonality. Finally, we provide an in-depth exploration of next-generation strategies, including bispecific antibodies, novel checkpoint targets, mRNA vaccines, antibody-drug conjugates, and advanced cellular therapies. While significant progress has been made, refining biomarker-driven selection and optimizing combination sequencing remain paramount. This thorough synthesis highlights promising future directions to overcome these hurdles and improve long-term survival in NSCLC.\n                  <\/jats:p>","DOI":"10.1186\/s13045-026-01791-w","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:24:29Z","timestamp":1777451069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current and future immunotherapies for NSCLC"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6917-868X","authenticated-orcid":false,"given":"Chu-Yu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-3957","authenticated-orcid":false,"given":"Yi-Fan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Ji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Mei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"1","key":"1791_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1791_CR2","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243\u201360.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1791_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1791_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"10308","key":"1791_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344\u201357.","journal-title":"Lancet"},{"issue":"21","key":"1791_CR6","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976\u201386.","journal-title":"N Engl J Med"},{"issue":"11","key":"1791_CR7","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal-Rubio J, D\u00f3mine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413\u201322.","journal-title":"Lancet Oncol"},{"issue":"17","key":"1791_CR8","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"10027","key":"1791_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"10066","key":"1791_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.","journal-title":"Lancet"},{"issue":"3","key":"1791_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","volume":"22","author":"Y Wang","year":"2025","unstructured":"Wang Y, Safi M, Hirsch FR, Lu S, Peters S, Govindan R, et al. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nat Rev Clin Oncol. 2025;22(3):200\u201314.","journal-title":"Nat Rev Clin Oncol"},{"issue":"22","key":"1791_CR12","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.3390\/ijms262211055","volume":"26","author":"GM Leone","year":"2025","unstructured":"Leone GM, Scuderi G, Fagone P, Mangano K. Directions of immunotherapy for non-small-cell lung cancer treatment: past, present and possible future. Int J Mol Sci. 2025;;26(22):11055. https:\/\/doi.org\/10.3390\/ijms262211055.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1791_CR13","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.3390\/curroncol31060258","volume":"31","author":"MP Capella","year":"2024","unstructured":"Capella MP, Pang SA, Magalhaes MA, Esfahani K. A Review of Immunotherapy in Non-Small-Cell Lung Cancer. Curr Oncol. 2024;31(6):3495\u2013512.","journal-title":"Curr Oncol"},{"issue":"11","key":"1791_CR14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1078-0432.CCR-21-3844","volume":"28","author":"O Akinboro","year":"2022","unstructured":"Akinboro O, Larkins E, Pai-Scherf LH, Mathieu LN, Ren Y, Cheng J, et al. FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced\/metastatic PD-L1 high NSCLC. Clin Cancer Res. 2022;28(11):2221\u201328. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3844.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1791_CR15","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score\u2009\u2265\u200950%. J Clin Oncol. 2021;39(21):2339\u201349.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1791_CR16","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/ijc.33399","volume":"148","author":"Y-L Wu","year":"2021","unstructured":"Wu Y-L, Zhang L, Fan Y, Zhou J, Zhang L, Zhou Q, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. Int J Cancer. 2021;148(9):2313\u201320.","journal-title":"Int J Cancer"},{"issue":"11","key":"1791_CR17","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.21.02885","volume":"41","author":"G de Castro","year":"2023","unstructured":"de Castro G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score\u2009\u2265\u20091% in the KEYNOTE-042 Study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(11):1986\u201391.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10183","key":"1791_CR18","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TS Mok","year":"2019","unstructured":"Mok TS, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"11","key":"1791_CR19","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","volume":"16","author":"J Jassem","year":"2021","unstructured":"Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, et al. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(11):1872\u201382.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"10274","key":"1791_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, G\u00fcm\u00fc\u015f M, Bondarenko I, \u00d6zg\u00fcro\u011flu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet (London England). 2021;397(10274):592\u2013604.","journal-title":"Lancet (London England)"},{"issue":"9","key":"1791_CR21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(23)00329-7","volume":"24","author":"M \u00d6zg\u00fcro\u011flu","year":"2023","unstructured":"\u00d6zg\u00fcro\u011flu M, Kilickap S, Sezer A, G\u00fcm\u00fc\u015f M, Bondarenko I, Gogishvili M, et al. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;;24(9):989\u20131001. https:\/\/doi.org\/10.1016\/S1470-2045(23)00329-7.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1791_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jtho.2025.03.033","volume":"20","author":"S Kilickap","year":"2025","unstructured":"Kilickap S, Baramidze A, Sezer A, \u00d6zg\u00fcro\u011flu M, Gumus M, Bondarenko I, et al. Cemiplimab monotherapy for first-line treatment of patients with advanced NSCLC with PD-L1 expression of 50% or higher: five-year outcomes of EMPOWER-lung 1. J Thorac Oncol. 2025;20(7):941\u201354. https:\/\/doi.org\/10.1016\/j.jtho.2025.03.033.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1791_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","volume":"18","author":"T Makharadze","year":"2023","unstructured":"Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, et al. Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2023;18(6):755\u201368.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"7","key":"1791_CR24","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S1470-2045(25)00198-6","volume":"26","author":"C Zhou","year":"2025","unstructured":"Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. Lancet Oncol. 2025;26(7):887\u201397.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1791_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","volume":"9","author":"J Zhong","year":"2024","unstructured":"Zhong J, Fei K, Wu L, Li B, Wang Z, Cheng Y, et al. Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal Transduct Target Ther. 2024;9(1):369.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1791_CR26","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol. 2023;41(11):1992\u20138.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1791_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924\u201337.","journal-title":"Lancet Oncol"},{"key":"1791_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","volume":"171","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, et al. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer (Amsterdam Netherlands). 2022;171:56\u201360.","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"12","key":"1791_CR29","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang Y, Sun J, Wang Z, Fang J, Yu Q, Han B, et al. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(12):2109\u201320.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"9","key":"1791_CR30","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","volume":"16","author":"S Lu","year":"2021","unstructured":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, et al. Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial. J Thorac Oncol. 2021;16(9):1512\u201322.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1791_CR31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2022.12.017","volume":"18","author":"C Zhou","year":"2023","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2023;18(5):628\u201339.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"(Suppl 3)","key":"1791_CR32","doi-asserted-by":"publisher","first-page":"102640","DOI":"10.1016\/j.esmoop.2024.102640","volume":"9","author":"C Zhou","year":"2024","unstructured":"Zhou C, Chen G, Huang Y, Zhou J, Lin L, Feng J, et al. 61P first-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study. ESMO Open. 2024;9(Suppl 3):102640. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102640.","journal-title":"ESMO Open"},{"issue":"24","key":"1791_CR33","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","volume":"378","author":"MA Socinski","year":"2018","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288\u2013301.","journal-title":"N Engl J Med"},{"issue":"10","key":"1791_CR34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazi\u00e8res J, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2020;15(10):1657\u201369.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"21","key":"1791_CR35","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D, Tafreshi A, G\u00fcm\u00fc\u015f M, Mazi\u00e8res J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040\u201351.","journal-title":"N Engl J Med"},{"issue":"11","key":"1791_CR36","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","volume":"41","author":"S Novello","year":"2023","unstructured":"Novello S, Kowalski DM, Luft A, G\u00fcm\u00fc\u015f M, Vicente D, Mazi\u00e8res J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(11):1999\u20132006.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"8","key":"1791_CR37","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.jtho.2020.03.028","volume":"15","author":"R Jotte","year":"2020","unstructured":"Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodr\u00edguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase\u00a0III trial. J Thorac Oncol. 2020;15(8):1351\u201360.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1791_CR38","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jtho.2021.04.011","volume":"16","author":"C Zhou","year":"2021","unstructured":"Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 2021;16(9):1501\u201311.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1791_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","volume":"7","author":"J Wang","year":"2021","unstructured":"Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(5):709\u201317.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1791_CR40","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","volume":"17","author":"S Ren","year":"2022","unstructured":"Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2022;17(4):544\u201357.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"(Suppl 3)","key":"1791_CR41","doi-asserted-by":"publisher","first-page":"102641","DOI":"10.1016\/j.esmoop.2024.102641","volume":"9","author":"C Zhou","year":"2024","unstructured":"Zhou C, Ren S, Chen J, Xu X, Cheng Y, Chen G, et al. 62P first-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial. ESMO Open. 2024;9(Suppl 3):102641. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102641.","journal-title":"ESMO Open"},{"issue":"2","key":"1791_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C, Hu Y, Arkania E, Kilickap S, Ying K, Xu F, et al. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell. 2024;42(2):198\u2013208.e3. https:\/\/doi.org\/10.1016\/j.ccell.2023.12.004.","journal-title":"Cancer Cell"},{"issue":"6","key":"1791_CR43","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee J-S, Ciuleanu T-E, Bernabe Caro R, Nishio M, Urban L, et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non\u2013small-cell lung cancer in CheckMate 227. J Clin Oncol. 2023;41(6):1200\u201312.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1791_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105123","volume":"10","author":"D Carbone","year":"2025","unstructured":"Carbone D, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, et al. Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA. ESMO Open. 2025;10(6):105123.","journal-title":"ESMO Open"},{"issue":"6","key":"1791_CR45","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1200\/JCO.22.00975","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41(6):1213\u201327.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"18","key":"1791_CR46","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(18):1558\u201365.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"12","key":"1791_CR47","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672\u201382.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1791_CR48","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501.","journal-title":"JAMA Oncol"},{"issue":"10185","key":"1791_CR49","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051\u20138.","journal-title":"Lancet"},{"issue":"25","key":"1791_CR50","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(25):2830\u20138.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"1791_CR51","doi-asserted-by":"crossref","unstructured":"Iyengar P, Hu C, Gomez DR, Timmerman RD, II CBS, Robinson CG, et al. NRG-LU002: Randomized phase II\/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2024;42(16suppl):8506.","DOI":"10.1200\/JCO.2024.42.16_suppl.8506"},{"issue":"9","key":"1791_CR52","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276\u201382.","journal-title":"JAMA Oncol"},{"issue":"20","key":"1791_CR53","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"1791_CR54","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301\u201311.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1791_CR55","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23(2):209\u201319.","journal-title":"Lancet Oncol"},{"issue":"(Suppl 3)","key":"1791_CR56","doi-asserted-by":"publisher","first-page":"102986","DOI":"10.1016\/j.esmoop.2024.102986","volume":"9","author":"J Bradley","year":"2024","unstructured":"Bradley J, Sugawara S, Lee K, Ostoros G, Demirkazik A, Zemanova M, et al. LBA1 durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9(Suppl 3):102986. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102986.","journal-title":"ESMO Open"},{"issue":"29","key":"1791_CR57","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.22.00227","volume":"40","author":"RS Herbst","year":"2022","unstructured":"Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(29):3383\u201393.","journal-title":"J Clin Oncol"},{"key":"1791_CR58","doi-asserted-by":"crossref","unstructured":"Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu QS, et al. Updated results from COAST, a phase 2 study of durvalumab (D)\u00b1oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.8046"},{"issue":"9","key":"1791_CR59","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1001\/jamaoncol.2024.1897","volume":"10","author":"HJ Ross","year":"2024","unstructured":"Ross HJ, Kozono D, Wang XF, Urbanic JJ, Williams TM, Nelson GD, et al. Atezolizumab before and after chemoradiation for unresectable stage III non-small cell lung cancer: a phase II nonrandomized controlled trial. JAMA Oncol. 2024;10(9):1212\u201319. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1897.","journal-title":"JAMA Oncol"},{"issue":"16suppl","key":"1791_CR60","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2024.42.16_suppl.8008","volume":"42","author":"H Liu","year":"2024","unstructured":"Liu H, Qiu B, Zhao Y, He W-z, Feng W, Zeng W, et al. A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). J Clin Oncol. 2024;42(16suppl):8008.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1791_CR61","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.annonc.2022.06.013","volume":"33","author":"F Cortiula","year":"2022","unstructured":"Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, et al. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol. 2022;33(9):893\u2013908.","journal-title":"Ann Oncol"},{"issue":"7","key":"1791_CR62","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ccell.2024.05.024","volume":"42","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024;42(7):1258\u2013e672.","journal-title":"Cancer Cell"},{"issue":"7","key":"1791_CR63","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2025.1115","volume":"11","author":"B Ricciuti","year":"2025","unstructured":"Ricciuti B, Fusco F, Cooper A, Garbo E, Pecci F, Aldea M, et al. Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non-small cell lung cancer. JAMA Oncol. 2025;11(7):735\u201341.","journal-title":"JAMA Oncol"},{"issue":"6","key":"1791_CR64","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.cllc.2024.06.007","volume":"25","author":"M Reck","year":"2024","unstructured":"Reck M, Nadal E, Girard N, Filippi AR, Martin LW, Gay CM, et al. MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC. Clin Lung Cancer. 2024;25(6):587\u2013e933.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1791_CR65","first-page":"398","volume":"2","author":"F Salv\u00e0","year":"2013","unstructured":"Salv\u00e0 F, Felip E. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Transl Lung Cancer Res. 2013;2(5):398\u2013402.","journal-title":"Transl Lung Cancer Res"},{"key":"1791_CR66","first-page":"1","volume":"42","author":"M Provencio","year":"2022","unstructured":"Provencio M, Calvo V, Romero A, Spicer JD, Cruz-Berm\u00fadez A. Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy. Am Soc Clin Oncol Educ Book. 2022;42:1\u201318.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"21","key":"1791_CR67","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO-24-01681","volume":"43","author":"E Felip","year":"2025","unstructured":"Felip E, Altorki N, Zhou C, Valli\u00e8res E, Csoszi T, Vynnychenko IO, et al. Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non\u2013small cell lung cancer (IMpower010): an open-label, randomized, phase III trial. J Clin Oncol. 2025;43(21):2343\u201349. https:\/\/doi.org\/10.1200\/JCO-24-01681.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1791_CR68","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274\u201386.","journal-title":"Lancet Oncol"},{"issue":"16suppl","key":"1791_CR69","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/JCO.2023.41.16_suppl.8520","volume":"41","author":"K Oselin","year":"2023","unstructured":"Oselin K, Shim BY, Okada M, Bryl M, Bonanno L, Demirag G, et al. Pembrolizumab vs placebo for early-stage non\u2013small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS\/KEYNOTE-091 study. J Clin Oncol. 2023;41(16suppl):8520.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1791_CR70","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"key":"1791_CR71","doi-asserted-by":"crossref","unstructured":"Forde PM, Spicer J, Provencio M, Mitsudomi T, Awad MM, Wang C, et al. Overall survival with neoadjuvant nivolumab (NIVO)+ chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816. American Society of Clinical Oncology; 2025.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8000"},{"issue":"10","key":"1791_CR72","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, Ni Y, Zhou Y, Tian F, et al. Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial. JAMA Oncol. 2023;9(10):1348\u201355.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1791_CR73","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.xcrm.2024.101615","volume":"5","author":"C Zhang","year":"2024","unstructured":"Zhang C, Sun Y-X, Yi D-C, Jiang B-Y, Yan L-X, Liu Z-D, et al. Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: phase 2 trial interim results (NEOTIDE\/CTONG2104). Cell Rep Med. 2024;5(7):101615. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101615.","journal-title":"Cell Rep Med"},{"issue":"6","key":"1791_CR74","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","volume":"389","author":"M Provencio","year":"2023","unstructured":"Provencio M, Nadal E, Gonzalez-Larriba JL, Martinez-Marti A, Bernabe R, Bosch-Barrera J, et al. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):504\u201313.","journal-title":"N Engl J Med"},{"issue":"11","key":"1791_CR75","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","volume":"25","author":"M Provencio","year":"2024","unstructured":"Provencio M, Nadal E, Insa A, Campelo RG, Casal J, D\u00f3mine M, et al. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(11):1453\u201364.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1791_CR76","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"1791_CR77","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2024.42.16_suppl.8011","volume":"42","author":"J Heymach","year":"2024","unstructured":"Heymach J, Reck M, Mitsudomi T, Taube JM, Spira AI, Chaft JE, et al. Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): an exploratory subgroup analysis of AEGEAN. J Clin Oncol. 2024;42(16_suppl):8011.","journal-title":"J Clin Oncol"},{"issue":"10459","key":"1791_CR78","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240\u201352.","journal-title":"Lancet"},{"issue":"6","key":"1791_CR79","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"issue":"19","key":"1791_CR80","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024;390(19):1756\u201369.","journal-title":"N Engl J Med"},{"issue":"3","key":"1791_CR81","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, Wang W, Zhang P, Fang W, et al. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024;331(3):201\u201311.","journal-title":"JAMA"},{"issue":"2","key":"1791_CR82","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, Chen Q, Chen C, Liu L, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13(2):119\u201329.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1791_CR83","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-023-01355-1","volume":"8","author":"M Shao","year":"2023","unstructured":"Shao M, Yao J, Wang Y, Zhao L, Li B, Li L, et al. Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial. Signal Transduct Target Therapy. 2023;8(1):146.","journal-title":"Signal Transduct Target Therapy"},{"issue":"16suppl","key":"1791_CR84","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1200\/JCO.2024.42.16_suppl.8048","volume":"42","author":"F Qiu","year":"2024","unstructured":"Qiu F, Fan J, Shao M, Yao J, Zhao L, Zhu L, et al. Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer. J Clin Oncol. 2024;42(16suppl):8048.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1791_CR85","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/fon-2024-0026","volume":"20","author":"X Zhang","year":"2024","unstructured":"Zhang X, Shao M, Yao J, Zhao L, Li L, Chen M, et al. NeoSCORE II: three vs four cycles of neoadjuvant sintilimab+ chemotherapy for squamous non-small-cell lung cancer. Future Oncol. 2024;20(3):121\u20139.","journal-title":"Future Oncol"},{"issue":"10","key":"1791_CR86","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","volume":"19","author":"PM Forde","year":"2024","unstructured":"Forde PM, Peters S, Donington J, Meadows-Shropshire S, Tran P, Lucherini S, et al. PL02. 08 perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816. J Thorac Oncol. 2024;19(10):S2.","journal-title":"J Thorac Oncol"},{"key":"1791_CR87","doi-asserted-by":"crossref","unstructured":"Deutsch JS, Cimino-Mathews A, Thompson E, Provencio M, Forde PM, Spicer J, et al. Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nat Med. 2024;30(1):218\u201328.","DOI":"10.1038\/s41591-023-02660-6"},{"issue":"7","key":"1791_CR88","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","volume":"19","author":"JB Hines","year":"2024","unstructured":"Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, et al. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. J Thorac Oncol. 2024;19(7):1108\u201316.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"1791_CR89","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2021;16(11):1909\u201324.","journal-title":"J Thorac Oncology: Official Publication Int Association Study Lung Cancer"},{"issue":"22","key":"1791_CR90","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"14","key":"1791_CR91","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020;383(14):1328\u201339.","journal-title":"N Engl J Med"},{"issue":"11","key":"1791_CR92","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41591-022-01977-y","volume":"28","author":"M Gogishvili","year":"2022","unstructured":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med. 2022;28(11):2374\u201380.","journal-title":"Nat Med"},{"issue":"33","key":"1791_CR93","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1200\/JCO.20.00131","volume":"38","author":"DM Waterhouse","year":"2020","unstructured":"Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, et al. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol. 2020;38(33):3863\u201373.","journal-title":"J Clin Oncol"},{"key":"1791_CR94","doi-asserted-by":"crossref","unstructured":"Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, et al. Four-year outcomes offirst-line nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced NSCLC: results of the randomized IFCT-1701\"DICIPLE\" phase III trial. J Thorac Oncol. 2026:103609. Epub ahead of print.","DOI":"10.1016\/j.jtho.2026.103609"},{"key":"1791_CR95","doi-asserted-by":"crossref","unstructured":"Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr., Reck M, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188\u201395.","DOI":"10.1016\/j.lungcan.2019.07.004"},{"key":"1791_CR96","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2019.11.019","volume":"127","author":"E Felip","year":"2020","unstructured":"Felip E, Ardizzoni A, Ciuleanu T, Cobo M, Laktionov K, Szilasi M, et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020;127:160\u201372.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1791_CR97","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","volume":"8","author":"G Middleton","year":"2020","unstructured":"Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020;8(9):895\u2013904.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1791_CR98","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Qu\u00e9r\u00e9 G, Misery L, Funck-Brentano E, Danlos FX, Routier E, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100\u201311.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1791_CR99","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","volume":"7","author":"NJ Shah","year":"2019","unstructured":"Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019;7(1):353.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1791_CR100","doi-asserted-by":"publisher","first-page":"111","DOI":"10.36401\/JIPO-23-28","volume":"7","author":"K Mustafayev","year":"2024","unstructured":"Mustafayev K, Mallet V, Torres HA. Management of hepatitis B virus and hepatitis C virus infections in patients with cancer receiving immune checkpoint inhibitors. J Immunother Precis Oncol. 2024;7(2):111\u201321.","journal-title":"J Immunother Precis Oncol"},{"issue":"4","key":"1791_CR101","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, et al. Non-small-cell Lung Cancer With Brain Metastasis at Presentation. Clin Lung Cancer. 2018;19(4):e373\u20139.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"1791_CR102","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","volume":"21","author":"SB Goldberg","year":"2020","unstructured":"Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655\u201363.","journal-title":"Lancet Oncol"},{"issue":"28","key":"1791_CR103","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1200\/JCO.22.02561","volume":"41","author":"E Nadal","year":"2023","unstructured":"Nadal E, Rodr\u00edguez-Abreu D, Sim\u00f3 M, Massut\u00ed B, Juan O, Huidobro G, et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17\/05). J Clin Oncol. 2023;41(28):4478\u201385.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1791_CR104","first-page":"100205","volume":"2","author":"AS Mansfield","year":"2021","unstructured":"Mansfield AS, Herbst RS, de Castro G Jr., Hui R, Peled N, Kim DW, et al. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep. 2021;2(8):100205.","journal-title":"JTO Clin Res Rep"},{"key":"1791_CR105","doi-asserted-by":"publisher","first-page":"115052","DOI":"10.1016\/j.ejca.2024.115052","volume":"212","author":"Y Tsuchiya-Kawano","year":"2024","unstructured":"Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, et al. Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004). Eur J Cancer. 2024;212:115052.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1791_CR106","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","volume":"18","author":"M Reck","year":"2023","unstructured":"Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, et al. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. J Thorac Oncol. 2023;18(8):1055\u201369.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1791_CR107","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(24)00643-0","volume":"26","author":"Y Xu","year":"2025","unstructured":"Xu Y, Chen K, Xu Y, Li H, Huang Z, Lu H, et al. Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26(1):74\u201384.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1791_CR108","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jtho.2025.02.004","volume":"20","author":"YS Li","year":"2025","unstructured":"Li YS, Yu Q, Bu Q, Lin L, Ning F, Zhao Y, et al. First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial. J Thorac Oncol. 2025;20(7):928\u201340.","journal-title":"J Thorac Oncol"},{"key":"1791_CR109","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ, Peterson J, Brown PD, Sheehan JP, Qui\u00f1ones-Hinojosa A, Zaorsky NG, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. Radiother Oncol. 2019;130:104\u201312.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1791_CR110","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijrobp.2018.02.175","volume":"101","author":"E Schapira","year":"2018","unstructured":"Schapira E, Hubbeling H, Yeap BY, Mehan WA Jr., Shaw AT, Oh K, et al. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2018;101(3):624\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1791_CR111","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563\u201380.","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"1791_CR112","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"1791_CR113","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jtho.2018.04.010","volume":"13","author":"SI Katz","year":"2018","unstructured":"Katz SI, Hammer M, Bagley SJ, Aggarwal C, Bauml JM, Thompson JC, et al. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(7):978\u201386.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"1791_CR114","doi-asserted-by":"publisher","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","volume":"4","author":"HJ Park","year":"2021","unstructured":"Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH, et al. Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e211136.","journal-title":"JAMA Netw Open"},{"issue":"15","key":"1791_CR115","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242\u201350.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1791_CR116","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"6230","key":"1791_CR117","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124\u20138.","journal-title":"Science"},{"issue":"12","key":"1791_CR118","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017;7(12):1420\u201335.","journal-title":"Cancer Discov"},{"issue":"7559","key":"1791_CR119","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135.","journal-title":"Nature"},{"issue":"10","key":"1791_CR120","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019;25(10):3074\u201383.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1791_CR121","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"2","key":"1791_CR122","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. Biodrugs. 2025;39(2):215\u201335.","journal-title":"Biodrugs"},{"issue":"3","key":"1791_CR123","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","volume":"7","author":"V Anagnostou","year":"2017","unstructured":"Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2017;7(3):264\u201376.","journal-title":"Cancer Discov"},{"key":"1791_CR124","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.","journal-title":"Nat Commun"},{"issue":"9","key":"1791_CR125","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"},{"issue":"7","key":"1791_CR126","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","volume":"24","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, et al. A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994\u20131004.","journal-title":"Nat Med"},{"issue":"6","key":"1791_CR127","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.21037\/tlcr-20-1252","volume":"9","author":"X Ge","year":"2020","unstructured":"Ge X, Zhang Z, Zhang S, Yuan F, Zhang F, Yan X, et al. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2020;9(6):2391\u2013400.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"1791_CR128","first-page":"100309","volume":"3","author":"S Xu","year":"2022","unstructured":"Xu S, Shukuya T, Tamura J, Shimamura S, Kurokawa K, Miura K, et al. Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis. JTO Clin Res Rep. 2022;3(4):100309.","journal-title":"JTO Clin Res Rep"},{"issue":"3","key":"1791_CR129","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","volume":"17","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022;17(3):399\u2013410.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"1791_CR130","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"24","author":"J Biton","year":"2018","unstructured":"Biton J, Mansuet-Lupo A, P\u00e9cuchet N, Alifano M, Ouakrim H, Arrondeau J, et al. TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. Clin Cancer Res. 2018;24(22):5710\u201323.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1791_CR131","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018;8(7):822\u201335.","journal-title":"Cancer Discov"},{"issue":"12","key":"1791_CR132","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017;23(12):3012\u201324.","journal-title":"Clin Cancer Res"},{"issue":"8038","key":"1791_CR133","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","volume":"635","author":"F Skoulidis","year":"2024","unstructured":"Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, et al. CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024;635(8038):462\u201371.","journal-title":"Nature"},{"key":"1791_CR134","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251386611","volume":"17","author":"F Skoulidis","year":"2025","unstructured":"Skoulidis F, Borghaei H, Garon EB, Leal TA, Kaufman J, Liu SV, et al. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study. Ther Adv Med Oncol. 2025;17:17588359251386611.","journal-title":"Ther Adv Med Oncol"},{"key":"1791_CR135","unstructured":"An Open-label, Phase I, Dose Escalation. Expansion Study of MGY825 in Adult Patients With Advanced Non-small Cell Lung Cancer [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05275868"},{"issue":"5","key":"1791_CR136","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jtho.2022.01.012","volume":"17","author":"MJ Ahn","year":"2022","unstructured":"Ahn MJ, Cho BC, Ou X, Walding A, Dymond AW, Ren S, et al. Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. J Thorac Oncol. 2022;17(5):718\u201323.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"1791_CR137","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","volume":"14","author":"JC Yang","year":"2019","unstructured":"Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, et al. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019;14(5):933\u20139.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1791_CR138","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med. 2022;387(2):120\u201331.","journal-title":"N Engl J Med"},{"issue":"15","key":"1791_CR139","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1002\/cam4.4659","volume":"11","author":"K Mortezaee","year":"2022","unstructured":"Mortezaee K, Majidpoor J. Checkpoint inhibitor\/interleukin-based combination therapy of cancer. Cancer Med. 2022;11(15):2934\u201343.","journal-title":"Cancer Med"},{"issue":"30","key":"1791_CR140","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1200\/JCO.23.00172","volume":"41","author":"A Diab","year":"2023","unstructured":"Diab A, Gogas H, Sandhu S, Long GV, Ascierto PA, Larkin J, et al. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. J Clin Oncol. 2023;41(30):4756\u201367.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1791_CR141","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","volume":"5","author":"S Lu","year":"2019","unstructured":"Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1\/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(8):1195\u2013204.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1791_CR142","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-02858-3","volume":"25","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang Y, Lu Y, Xu Y, Xu J, Zhong H, et al. Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer. Respir Res. 2024;25(1):233.","journal-title":"Respir Res"},{"key":"1791_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108463","volume":"202","author":"SPL Saw","year":"2025","unstructured":"Saw SPL, Takano A, Zhou S, Hlaing NO, James A, Joseph C, et al. EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer. Lung Cancer. 2025;202:108463.","journal-title":"Lung Cancer"},{"issue":"10","key":"1791_CR144","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.annonc.2024.06.014","volume":"35","author":"A Di Federico","year":"2024","unstructured":"Di Federico A, Alden SL, Smithy JW, Ricciuti B, Alessi JV, Wang X, et al. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024;35(10):902\u201313.","journal-title":"Ann Oncol"},{"issue":"2","key":"1791_CR145","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"key":"1791_CR146","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fonc.2019.01161","volume":"9","author":"Y Wu","year":"2019","unstructured":"Wu Y, Xu J, Du C, Wu Y, Xia D, Lv W, et al. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2019;9:1161.","journal-title":"Front Oncol"},{"issue":"8","key":"1791_CR147","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"6411","key":"1791_CR148","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593. https:\/\/doi.org\/10.1126\/science.aar3593.","journal-title":"Science"},{"issue":"10030","key":"1791_CR149","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837\u201346.","journal-title":"Lancet"},{"issue":"16","key":"1791_CR150","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","volume":"24","author":"BW Higgs","year":"2018","unstructured":"Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, et al. Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. Clin Cancer Res. 2018;24(16):3857\u201366.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1791_CR151","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","volume":"29","author":"V Anagnostou","year":"2023","unstructured":"Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, et al. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023;29(10):2559\u201369.","journal-title":"Nat Med"},{"key":"1791_CR152","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2023.10.055","volume":"34","author":"M Reck","year":"2023","unstructured":"Reck M, Gale D, Harpole D, Taube J, Mitsudomi T, Hochmair M, et al. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Ann Oncol. 2023;34:S1300.","journal-title":"Ann Oncol"},{"issue":"1","key":"1791_CR153","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41392-023-01700-4","volume":"8","author":"SY Liu","year":"2023","unstructured":"Liu SY, Dong S, Yang XN, Liao RQ, Jiang BY, Wang Q, et al. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study. Signal Transduct Target Ther. 2023;8(1):442.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1791_CR154","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan Y, Zhang JT, Gao X, Chen ZY, Yan B, Tan PX, et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell. 2023;41(10):1763-73.e4.","journal-title":"Cancer Cell"},{"key":"1791_CR155","unstructured":"Phase A, Randomized III. Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1) [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04385368"},{"key":"1791_CR156","unstructured":"Phase A, Randomized III, Multicenter. Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04642469"},{"key":"1791_CR157","unstructured":"Minimal Residual Disease (MRD)-Guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB Non-small Cell Lung Cancer (NSCLC): a Randomized Controlled Phase II Study (Seagull) [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05286957"},{"key":"1791_CR158","unstructured":"Consolidation Toripalimab Therapy Guided by Circulating Tumor DNA (ctDNA)-Minimal Residual Disease (MRD) for Completely Resected Stage IB-IIIA Non-small-cell Lung Cancer (Without EGFR or ALK Alterations for Nonsquamous Lung Cancer) [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06426511"},{"issue":"6371","key":"1791_CR159","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science"},{"issue":"6","key":"1791_CR160","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","volume":"29","author":"L Derosa","year":"2018","unstructured":"Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437\u201344.","journal-title":"Ann Oncol"},{"issue":"2","key":"1791_CR161","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022;28(2):315\u201324.","journal-title":"Nat Med"},{"issue":"13","key":"1791_CR162","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1016\/j.cell.2024.05.029","volume":"187","author":"L Derosa","year":"2024","unstructured":"Derosa L, Iebba V, Silva CAC, Piccinno G, Wu G, Lordello L, et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell. 2024;187(13):3373\u2013e8916.","journal-title":"Cell"},{"issue":"1","key":"1791_CR163","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/s41598-025-89406-1","volume":"15","author":"A Grenda","year":"2025","unstructured":"Grenda A, Iwan E, Ku\u017anar-Kami\u0144ska B, Bomba A, Bieli\u0144ska K, Krawczyk P, et al. Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients. Sci Rep. 2025;15(1):6139.","journal-title":"Sci Rep"},{"issue":"6371","key":"1791_CR164","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science"},{"issue":"8","key":"1791_CR165","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy B, Lenehan JG, Miller WH Jr., Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med. 2023;29(8):2121\u201332.","journal-title":"Nat Med"},{"issue":"6375","key":"1791_CR166","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","volume":"359","author":"D Chowell","year":"2018","unstructured":"Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582\u20137.","journal-title":"Science"},{"issue":"11","key":"1791_CR167","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1038\/s41591-019-0639-4","volume":"25","author":"D Chowell","year":"2019","unstructured":"Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019;25(11):1715\u201320.","journal-title":"Nat Med"},{"issue":"6","key":"1791_CR168","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-18-1127","volume":"79","author":"V Anagnostou","year":"2019","unstructured":"Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Res. 2019;79(6):1214\u201325.","journal-title":"Cancer Res"},{"issue":"10","key":"1791_CR169","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","volume":"25","author":"K Joshi","year":"2019","unstructured":"Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med. 2019;25(10):1549\u201359.","journal-title":"Nat Med"},{"issue":"1","key":"1791_CR170","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","volume":"8","author":"J Han","year":"2020","unstructured":"Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, et al. TCR Repertoire Diversity of Peripheral PD-1(+)CD8(+) T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):146\u201354.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"1791_CR171","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/1078-0432.CCR-22-2469","volume":"29","author":"ML Frank","year":"2023","unstructured":"Frank ML, Lu K, Erdogan C, Han Y, Hu J, Wang T, et al. T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy. Clin Cancer Res. 2023;29(6):994\u20131008.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1791_CR172","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596\u2013e61414.","journal-title":"Cell"},{"issue":"1","key":"1791_CR173","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41392-024-02060-3","volume":"9","author":"X Ai","year":"2024","unstructured":"Ai X, Jia B, He Z, Zhang J, Zhuo M, Zhao J, et al. Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432). Signal Transduct Target Ther. 2024;9(1):350.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1791_CR174","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"1791_CR175","doi-asserted-by":"crossref","unstructured":"Zhou C, Chen J, Wu L, Wang L, Xiong A, Liu B, et al. editors. Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2. Proceedings of the 2024 World Conference on Lung Cancer; 2024.","DOI":"10.1016\/j.jtho.2024.09.012"},{"issue":"10481","key":"1791_CR176","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","volume":"405","author":"A Xiong","year":"2025","unstructured":"Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet. 2025;405(10481):839\u201349.","journal-title":"Lancet"},{"issue":"10515","key":"1791_CR177","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","volume":"406","author":"Z Chen","year":"2025","unstructured":"Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025;406(10515):2078\u201388.","journal-title":"Lancet"},{"issue":"3","key":"1791_CR178","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, et al. KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial. Cell Rep Med. 2024;5(3):101470.","journal-title":"Cell Rep Med"},{"key":"1791_CR179","doi-asserted-by":"publisher","first-page":"S1646","DOI":"10.1016\/j.annonc.2024.10.680","volume":"35","author":"B Han","year":"2024","unstructured":"Han B, Zhang Y. 647P a phase Ib\/II study of second-line cadonilimab, anlotinib and docetaxel in patients with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer. Ann Oncol. 2024;35:S1646.","journal-title":"Ann Oncol"},{"issue":"3","key":"1791_CR180","doi-asserted-by":"publisher","first-page":"101470","DOI":"10.1016\/j.xcrm.2024.101470","volume":"5","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, et al. KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: a multicenter phase 2 trial. Cell Rep Med. 2024;5(3):101470. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101470.","journal-title":"Cell Rep Med"},{"key":"1791_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100762","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhao Y, Meng X, Huang Y, Fang W, Yang Y, et al. 133P the efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: a single-arm, open-label, multicenter phase II clinical trial. Immuno-Oncology and Technology. 2024. https:\/\/doi.org\/10.1016\/j.iotech.2024.100762.","journal-title":"Immuno-Oncology and Technology"},{"key":"1791_CR182","doi-asserted-by":"publisher","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","volume":"33","author":"M Ahn","year":"2022","unstructured":"Ahn M, Kim S, Costa EC, Rodr\u00edguez L, Oliveira J, Molla MI, et al. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-na\u00efve (1L) non-small cell lung cancer (NSCLC): A phase Ib\/II trial. Ann Oncol. 2022;33:S1423.","journal-title":"Ann Oncol"},{"key":"1791_CR183","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClin Med. 2023;62:102106. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102106.","journal-title":"EClin Med"},{"issue":"12","key":"1791_CR184","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.jtho.2023.08.018","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, Lee JS, Wu Y-L, Cicin I, Dols MC, Ahn M-J, et al. Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, programmed death-ligand 1\u2013high advanced NSCLC: a randomized, open-label, phase 3 trial. J Thorac Oncol. 2023;18(12):1731\u201342.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"1791_CR185","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.annonc.2021.11.008","volume":"33","author":"I Attili","year":"2022","unstructured":"Attili I, Passaro A, de Marinis F. Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials. Ann Oncol. 2022;33(2):119\u201322.","journal-title":"Ann Oncol"},{"issue":"1","key":"1791_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01800-3","volume":"22","author":"X Chu","year":"2023","unstructured":"Chu X, Tian W, Wang Z, Zhang J, Zhou R. Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol Cancer. 2023;22(1):93.","journal-title":"Mol Cancer"},{"issue":"1","key":"1791_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1791_CR188","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"6","key":"1791_CR189","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392.","journal-title":"Lancet Oncol"},{"key":"1791_CR190","unstructured":"Phase A, Randomized IIIII, Double-Blind. Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin\/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin\/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04619797"},{"key":"1791_CR191","unstructured":"Phase A, Randomized III, Double-Blinded P-C. Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer [Internet]. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04294810"},{"issue":"2","key":"1791_CR192","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","volume":"8","author":"T Maruhashi","year":"2020","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J Immunother Cancer. 2020;8(2):e001014. https:\/\/doi.org\/10.1136\/jitc-2020-001014.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1791_CR193","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"CT Huang","year":"2004","unstructured":"Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503\u201313.","journal-title":"Immunity"},{"issue":"12","key":"1791_CR194","doi-asserted-by":"publisher","first-page":"101831","DOI":"10.1016\/j.xcrm.2024.101831","volume":"5","author":"JP Gu\u00e9gan","year":"2024","unstructured":"Gu\u00e9gan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med. 2024;5(12):101831.","journal-title":"Cell Rep Med"},{"key":"1791_CR195","doi-asserted-by":"publisher","first-page":"S754","DOI":"10.1016\/j.annonc.2023.09.2346","volume":"34","author":"E Carcereny","year":"2023","unstructured":"Carcereny E, Felip E, Majem M, de Sp\u00e9ville BD, Clay T, Bondarenko I, et al. 1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II). Ann Oncol. 2023;34:S754.","journal-title":"Ann Oncol"},{"issue":"4","key":"1791_CR196","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S1556-0864(23)00265-4","volume":"18","author":"M Majem","year":"2023","unstructured":"Majem M, Forster M, Krebs MG, Peguero J, Clay T, Felip E, et al. 11MO final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1\/PD-L1 inhibitors. J Thorac Oncol. 2023;18(4):S43\u20134.","journal-title":"J Thorac Oncol"},{"issue":"6","key":"1791_CR197","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-024-02965-0","volume":"30","author":"M Schuler","year":"2024","unstructured":"Schuler M, Cuppens K, Pl\u00f6nes T, Wiesweg M, Du Pont B, Hegedus B, et al. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nat Med. 2024;30(6):1602\u201311.","journal-title":"Nat Med"},{"issue":"11","key":"1791_CR198","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","volume":"72","author":"N Sauer","year":"2023","unstructured":"Sauer N, Janicka N, Szlasa W, Skinderowicz B, Ko\u0142odzi\u0144ska K, Dwernicka W, et al. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunol Immunother. 2023;72(11):3405\u201325.","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"1791_CR199","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-24-2131","volume":"30","author":"G Curigliano","year":"2024","unstructured":"Curigliano G, Curigliano H, Mach N, Doi T, Tai D, Forde PM, et al. Correction: Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2024;30(17):3957.","journal-title":"Clin Cancer Res"},{"key":"1791_CR200","doi-asserted-by":"crossref","unstructured":"Davar D, Eroglu Z, Milhem M, Becerra C, Gutierrez M, Ribas A, et al. 596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced\/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD (L)-1 therapy. BMJ Specialist Journals; 2023.","DOI":"10.1136\/jitc-2023-SITC2023.0596"},{"key":"1791_CR201","doi-asserted-by":"crossref","unstructured":"Johnson ML, Fox W, Lee Y-G, Lee KH, Ahn HK, Kim Y-C, et al. ARC-7: Randomized phase 2 study of domvanalimab+ zimberelimab\u00b1etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC). American Society of Clinical Oncology; 2022.","DOI":"10.1200\/JCO.2022.40.36_suppl.397600"},{"key":"1791_CR202","unstructured":"Merck Announces Findings From Phase 2 KEYVIBE-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer2023. Available from: https:\/\/www.merck.com\/news\/merck-announces-findings-from-phase-2-keyvibe-002-trial-evaluating-an-investigational-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small-cell-lung\/"},{"issue":"Suppl","key":"1791_CR203","doi-asserted-by":"publisher","first-page":"100593","DOI":"10.1016\/j.iotech.2023.100593","volume":"20","author":"N Peled","year":"2023","unstructured":"Peled N, Mazieres J, Kowalski D, Lam W, Hochmair M, Majem M, et al. 121P MK-7684A (vibostolimab [vibo] plus pembrolizumab [pembro] coformulation) with\/without docetaxel in metastatic NSCLC after platinum-chemotherapy (chemo) and immunotherapy. Immuno-Oncology and Technology. 2023;20(Suppl):100593. https:\/\/doi.org\/10.1016\/j.iotech.2023.100593.","journal-title":"Immuno-Oncology and Technology"},{"issue":"8Supplement2","key":"1791_CR204","doi-asserted-by":"publisher","first-page":"CT051","DOI":"10.1158\/1538-7445.AM2025-CT051","volume":"85","author":"S Peters","year":"2025","unstructured":"Peters S, Herbst R, Horinouchi H, Paz-Ares L, Johnson M, Solomon B, et al. Abstract CT051: SKYSCRAPER-01: a phase III, randomized trial of tiragolumab (tira)+ atezolizumab (atezo) versus placebo (pbo)+ atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable\/metastatic NSCLC. Cancer Res. 2025;85(8Supplement2):CT051\u2013CT.","journal-title":"Cancer Res"},{"issue":"Suppl","key":"1791_CR205","doi-asserted-by":"publisher","first-page":"101025","DOI":"10.1016\/j.iotech.2024.101025","volume":"24","author":"M Socinski","year":"2024","unstructured":"Socinski M, Abreu DR, Lee D, Cappuzzo F, Nishio M, Lovly C, et al. LBA2 SKYSCRAPER-06: efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira+ atezo+ chemo) vs pembrolizumab plus chemotherapy (pembro+ chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC). Immuno-Oncology and Technology. 2024;24(Suppl):101025. https:\/\/doi.org\/10.1016\/j.iotech.2024.101025.","journal-title":"Immuno-Oncology and Technology"},{"key":"1791_CR206","doi-asserted-by":"crossref","unstructured":"Naidoo J, Peters S, Runglodvatana Y, Li JY-C, Fong CH, Ho GF et al. Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1\u2013high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1. Lung Cancer. 2026;215:109316.","DOI":"10.1016\/j.lungcan.2026.109316"},{"key":"1791_CR207","unstructured":"Randomized A, Open-Label. Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05502237"},{"key":"1791_CR208","unstructured":"Phase A, Randomised III. Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy [Internet]. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05211895"},{"key":"1791_CR209","doi-asserted-by":"publisher","first-page":"S1243","DOI":"10.1016\/j.annonc.2024.08.2295","volume":"35","author":"N Girard","year":"2024","unstructured":"Girard N, Burotto M, Paz-Ares L, Reck M, Schenker M, Lingua A, et al. LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO+ PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study. Ann Oncol. 2024;35:S1243\u20134.","journal-title":"Ann Oncol"},{"key":"1791_CR210","unstructured":"Jonsson SI. Relatlimab Plus Nivolumab and Chemo Improves Clinical Benefit in Stage IV NSCLC2023. Available from: https:\/\/www.onclive.com\/view\/relatlimab-plus-nivolumab-and-chemo-improves-clinical-benefit-in-stage-iv-nsclc"},{"key":"1791_CR211","unstructured":"Phase A. 3, Randomized, Open-label Study of Nivolumab\u2009+\u2009Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression\u2009\u2265\u20091% [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06561386"},{"key":"1791_CR212","unstructured":"Randomized A. Double-Blind Phase 2\/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1\u2009\u2265\u200950% [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05785767"},{"issue":"Suppl","key":"1791_CR213","volume":"28","author":"E Felip","year":"2025","unstructured":"Felip E, Nahra R, Novello S, Velcheti V, Tufman A, Goetze TO, et al. 241MO Results fromCOSTAR lung: cobolimab + dostarlimab + docetaxel and dostarlimab + docetaxel versus docetaxel alone in patients with previously treatedadvanced\/metastatic (A\/M) non-small cell lung cancer (NSCLC). Ann Oncol. 2025;28(Suppl):101440.","journal-title":"Ann Oncol"},{"key":"1791_CR214","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2147\/ITT.S260429","volume":"10","author":"M Tagliamento","year":"2021","unstructured":"Tagliamento M, Agostinetto E, Borea R, Brand\u00e3o M, Poggio F, Addeo A, et al. VISTA: A Promising Target for Cancer Immunotherapy? Immunotargets Ther. 2021;10:185\u2013200.","journal-title":"Immunotargets Ther"},{"issue":"9","key":"1791_CR215","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/2326-6066.CIR-18-0489","volume":"7","author":"W Xu","year":"2019","unstructured":"Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta HM, et al. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunol Res. 2019;7(9):1497\u2013510.","journal-title":"Cancer Immunol Res"},{"key":"1791_CR216","doi-asserted-by":"publisher","first-page":"1225081","DOI":"10.3389\/fonc.2023.1225081","volume":"13","author":"RJ Noelle","year":"2023","unstructured":"Noelle RJ, Lines JL, Lewis LD, Martell RE, Guillaudeux T, Lee SW, et al. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights. Front Oncol. 2023;13:1225081.","journal-title":"Front Oncol"},{"issue":"1","key":"1791_CR217","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01733-x","volume":"22","author":"C Xia","year":"2023","unstructured":"Xia C, Yin S, To KKW, Fu L. CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer. 2023;22(1):44.","journal-title":"Mol Cancer"},{"issue":"21","key":"1791_CR218","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","volume":"26","author":"L Borst","year":"2020","unstructured":"Borst L, van der Burg SH, van Hall T. The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin Cancer Res. 2020;26(21):5549\u201356.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1791_CR219","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","volume":"13","author":"T Cascone","year":"2023","unstructured":"Cascone T, Kar G, Spicer JD, Garc\u00eda-Campelo R, Weder W, Daniel DB, et al. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discov. 2023;13(11):2394\u2013411.","journal-title":"Cancer Discov"},{"key":"1791_CR220","doi-asserted-by":"crossref","unstructured":"Barlesi F, Goldberg SB, Mann H, Gopinathan A, Newton MD, Aggarwal C. Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9). American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8610"},{"issue":"2","key":"1791_CR221","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","volume":"25","author":"AE Moran","year":"2013","unstructured":"Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013;25(2):230\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"1791_CR222","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10555-024-10184-9","volume":"43","author":"B Thapa","year":"2024","unstructured":"Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, et al. OX40\/OX40 ligand and its role in precision immune oncology. Cancer Metastasis Rev. 2024;43(3):1001\u201313.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1791_CR223","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01826-z","volume":"9","author":"N Yin","year":"2024","unstructured":"Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, et al. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct Target Ther. 2024;9(1):126.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1791_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00241-8","volume":"6","author":"W Lei","year":"2025","unstructured":"Lei W, Zhou K, Lei Y, Li Q, Zhu H. Cancer vaccines: platforms and current progress. Mol Biomed. 2025;6(1):3.","journal-title":"Mol Biomed"},{"issue":"2","key":"1791_CR225","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41573-024-01081-5","volume":"24","author":"M Graciotti","year":"2025","unstructured":"Graciotti M, Kandalaft LE. Vaccines for cancer prevention: exploring opportunities and navigating challenges. Nat Rev Drug Discov. 2025;24(2):134\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1791_CR226","doi-asserted-by":"publisher","first-page":"127","DOI":"10.33696\/immunology.5.178","volume":"5","author":"TA Addissouky","year":"2023","unstructured":"Addissouky TA, El Sayed IET, Ali MM, Wang Y, El Baz A, Khalil AA, et al. Can vaccines stop cancer before it starts? Assessing the promise of prophylactic immunization against high-risk preneoplastic lesions. J Cell Immunol. 2023;5(4):127\u201340.","journal-title":"J Cell Immunol"},{"issue":"6","key":"1791_CR227","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360\u201378.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1791_CR228","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(1):59\u201368.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1791_CR229","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","volume":"17","author":"JF Vansteenkiste","year":"2016","unstructured":"Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(6):822\u201335.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1791_CR230","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","volume":"17","author":"E Quoix","year":"2016","unstructured":"Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial. Lancet Oncol. 2016;17(2):212\u201323.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1791_CR231","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1158\/1078-0432.CCR-15-1509","volume":"22","author":"\u00d6 T\u00fcreci","year":"2016","unstructured":"T\u00fcreci \u00d6, Vormehr M, Diken M, Kreiter S, Huber C, Sahin U. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res. 2016;22(8):1885\u201396.","journal-title":"Clin Cancer Res"},{"issue":"7662","key":"1791_CR232","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222\u20136.","journal-title":"Nature"},{"issue":"7528","key":"1791_CR233","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572\u20136.","journal-title":"Nature"},{"issue":"4","key":"1791_CR234","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. MRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"10427","key":"1791_CR235","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632\u201344.","journal-title":"Lancet"},{"key":"1791_CR236","unstructured":"Phase A. 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002) [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06077760"},{"key":"1791_CR237","unstructured":"Phase A. 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06623422"},{"issue":"9","key":"1791_CR238","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010\u2013e2611.","journal-title":"Cancer Cell"},{"issue":"8089","key":"1791_CR239","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647(8089):488\u201397.","journal-title":"Nature"},{"issue":"2","key":"1791_CR240","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72(2):165\u201382.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1791_CR241","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"key":"1791_CR242","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","volume":"75","author":"BE Nelson","year":"2024","unstructured":"Nelson BE, Meric-Bernstam F. Leveraging TROP2 antibody-drug conjugates in solid tumors. Annu Rev Med. 2024;75:31\u201348.","journal-title":"Annu Rev Med"},{"key":"1791_CR243","doi-asserted-by":"crossref","unstructured":"Reck M, Patel JD, Gray JE, Reguart N, Cobo M, Pradera JF et al. First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study. J Thorac Oncol. 2025;21(3):103509.","DOI":"10.1016\/j.jtho.2025.10.016"},{"issue":"11","key":"1791_CR244","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1038\/s41591-025-03883-5","volume":"31","author":"S Hong","year":"2025","unstructured":"Hong S, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2025;31(11):3654\u201361.","journal-title":"Nat Med"},{"issue":"16_suppl","key":"1791_CR245","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1200\/JCO.2025.43.16_suppl.3036","volume":"43","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Q, Han L, Ouyang W, Li X, Yao Y, et al. Results from a phase 1\/2 study of 7MW3711: a novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer. J Clin Oncol. 2025;43(16_suppl):3036.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"1791_CR246","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2025.43.16_suppl.3025","volume":"43","author":"J Wang","year":"2025","unstructured":"Wang J, Wan R, Zeng S, Wu L, Zhong H, Wu J, et al. A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced\/metastatic solid tumors. J Clin Oncol. 2025;43(16suppl):3025.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1791_CR247","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.","journal-title":"Signal Transduct Target Ther"},{"key":"1791_CR248","doi-asserted-by":"crossref","unstructured":"Saltos AN, Arrowood C, Beasley G, Ronald J, El-Haddad G, Guerra-Guevara L, et al. A phase 1 first-in-human study of interferon beta (IFN\u03b2) and membrane-stable CD40L expressing oncolytic virus (MEM-288) in solid tumors including non\u2013small-cell lung cancer (NSCLC). American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.2569"},{"key":"1791_CR249","unstructured":"Phase I. Study of MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) [Internet]. 2021. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05076760"},{"key":"1791_CR250","unstructured":"A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy\u2009+\u2009Physician\u2019s Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06463665"},{"key":"1791_CR251","doi-asserted-by":"publisher","first-page":"e28344","DOI":"10.4161\/onci.28344","volume":"3","author":"F Aranda","year":"2014","unstructured":"Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Herv\u00e9 Fridman W, et al. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology. 2014;3:e28344.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1791_CR252","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1791_CR253","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.3390\/cimb45110566","volume":"45","author":"HY Ma","year":"2023","unstructured":"Ma HY, Das J, Prendergast C, De Jong D, Braumuller B, Paily J, et al. Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer. Curr Issues Mol Biol. 2023;45(11):9019\u201338.","journal-title":"Curr Issues Mol Biol"},{"issue":"1","key":"1791_CR254","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","volume":"16","author":"V Albarr\u00e1n-Fern\u00e1ndez","year":"2025","unstructured":"Albarr\u00e1n-Fern\u00e1ndez V, Angelats L, Delgado J, Gros A, Urbano-Ispizua \u00c1, Guedan S, et al. Unlocking the potential of engineered immune cell therapy for solid tumors. Nat Commun. 2025;16(1):1144.","journal-title":"Nat Commun"},{"issue":"12","key":"1791_CR255","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Z, Ding Y, Fang Y, Wang P, Chu W, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1791_CR256","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","volume":"31","author":"CA Jaeger-Ruckstuhl","year":"2025","unstructured":"Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, MacMillan HR, Wu QV, Muhunthan V, et al. Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies. Clin Cancer Res. 2025;31(3):503\u201314.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1791_CR257","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, O\u2019Cearbhaill RE, et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363.","journal-title":"Cancer Discov"},{"issue":"1","key":"1791_CR258","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0812-8","volume":"12","author":"Q He","year":"2019","unstructured":"He Q, Jiang X, Zhou X, Weng J. Targeting cancers through TCR-peptide\/MHC interactions. J Hematol Oncol. 2019;12(1):139.","journal-title":"J Hematol Oncol"},{"key":"1791_CR259","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-019-0070-9","volume":"4","author":"D Li","year":"2019","unstructured":"Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, et al. Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 2019;4:35.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1791_CR260","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"issue":"21","key":"1791_CR261","doi-asserted-by":"publisher","first-page":"e175790","DOI":"10.1172\/JCI175790","volume":"134","author":"AS Bear","year":"2024","unstructured":"Bear AS, Nadler RB, O\u2019Hara MH, Stanton KL, Xu C, Saporito RJ, et al. Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest. 2024;134(21):e175790. https:\/\/doi.org\/10.1172\/JCI175790.","journal-title":"J Clin Invest"},{"issue":"2","key":"1791_CR262","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ygyno.2018.05.024","volume":"150","author":"P Mayor","year":"2018","unstructured":"Mayor P, Starbuck K, Zsiros E. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol. 2018;150(2):361\u20139.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1791_CR263","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","volume":"42","author":"AA Sarnaik","year":"2024","unstructured":"Sarnaik AA, Hwu P, Mul\u00e9 JJ, Pilon-Thomas S. Tumor-infiltrating lymphocytes: a new hope. Cancer Cell. 2024;42(8):1315\u20138.","journal-title":"Cancer Cell"},{"issue":"23","key":"1791_CR264","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387(23):2113\u201325.","journal-title":"N Engl J Med"},{"issue":"17","key":"1791_CR265","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","volume":"19","author":"MJ Besser","year":"2013","unstructured":"Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19(17):4792\u2013800.","journal-title":"Clin Cancer Res"},{"key":"1791_CR266","doi-asserted-by":"crossref","unstructured":"Shields MD, Marin-Acevedo JA, Pellini B, editors. Immunotherapy for advanced non-small cell lung cancer: a decade of progress. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting; 2021.","DOI":"10.1200\/EDBK_321483"},{"issue":"2","key":"1791_CR267","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","volume":"21","author":"SA Rosenberg","year":"2009","unstructured":"Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233\u201340.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"1791_CR268","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1080\/0284186X.2023.2228991","volume":"62","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li S, Zhang C, Mu Z, Chen K, Xu Z. Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study. Acta Oncol. 2023;62(8):853\u201360.","journal-title":"Acta Oncol"},{"issue":"8","key":"1791_CR269","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021;27(8):1410\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"1791_CR270","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, Doger de Sp\u00e9ville B, Gettinger SN, H\u00e4fliger S, Sukari A, et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non\u2013small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14(8):1389\u2013402.","journal-title":"Cancer Discov"},{"issue":"1","key":"1791_CR271","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27(1):74\u201395.","journal-title":"Cell Res"},{"issue":"1","key":"1791_CR272","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00262-018-2257-2","volume":"68","author":"W Zhang","year":"2019","unstructured":"Zhang W, Lu X, Cui P, Piao C, Xiao M, Liu X, et al. Phase I\/II clinical trial of a Wilms\u2019 tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Cancer Immunol Immunother. 2019;68(1):121\u201330.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1791_CR273","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023;8(1):450.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1791_CR274","doi-asserted-by":"publisher","first-page":"101516","DOI":"10.1016\/j.xcrm.2024.101516","volume":"5","author":"J Ingels","year":"2024","unstructured":"Ingels J, De Cock L, Stevens D, Mayer RL, Th\u00e9ry F, Sanchez GS, et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep Med. 2024;5(5):101516.","journal-title":"Cell Rep Med"},{"key":"1791_CR275","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124.","journal-title":"Front Immunol"},{"issue":"1","key":"1791_CR276","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22(1):194.","journal-title":"Mol Cancer"},{"issue":"3","key":"1791_CR277","doi-asserted-by":"publisher","first-page":"e008585","DOI":"10.1136\/jitc-2023-008585","volume":"12","author":"MG Choi","year":"2024","unstructured":"Choi MG, Son GW, Choi MY, Jung JS, Rho JK, Ji W, et al. Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and\/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I\/IIa clinical study. J Immunother Cancer. 2024;12(3):e008585. https:\/\/doi.org\/10.1136\/jitc-2023-008585.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1791_CR278","doi-asserted-by":"publisher","first-page":"e186890","DOI":"10.1172\/jci.insight.186890","volume":"10","author":"MA Villalona-Calero","year":"2025","unstructured":"Villalona-Calero MA, Tian L, Li X, Palmer JM, Aceves C, Meisen H, et al. Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors. JCI Insight. 2025;10(6):e186890. https:\/\/doi.org\/10.1172\/jci.insight.186890.","journal-title":"JCI Insight"},{"key":"1791_CR279","doi-asserted-by":"crossref","unstructured":"Levy B, Paz-Ares L, Lin CC, Herbert S, Yang TY, Tolcher A, et al. Datopotamab Deruxtecan PlusPembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. JThorac Oncol. 2026:103688.","DOI":"10.1016\/j.jtho.2026.103688"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01791-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01791-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01791-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:03:33Z","timestamp":1779966213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01791-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":279,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01791-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was updated to correct the equal contribution markers and remove XML elements from the references.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}